Biomeme PCR Device, assays, and sample preparation are currently utilized for molecular detection in an active research project that cannot be fulfilled by other resources. If a different assay manufacturer were to be used, resulting data would not be comparable to the established method of detection and could not be used to substantiate the efficacy of a modified assay that aims to resolve detection shortfalls for current life-threatening illnesses. It is anticipated that award will be made on or before September 30, 2017 with a twenty-four (24) month period of performance. This is NOT a request for competitive quotes. This notice is for informational purposes only. A determination by the Government not to compete this action rests solely with the discretion of the Government. POC: Matthew Shigley, Agreements Officer, DOI/IBC, Acquisition Services Directorate, 381 Elden Street, Suite 4000, Herndon, VA 20170, matthew_shigley@ibc.doi.gov.